Author

T. Hermanus

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 4

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Research Focus:host-pathogen & immune response· 4 Organism:human· 3 Assay:proteomics· 2 Organism:mouse· 1 Organism:rat· 1

Frequent Co-Authors

L. Morris· 3 shared P. Kgagudi· 3 shared B. E. Lambson· 2 shared F. Ayres· 2 shared M. Boswell· 2 shared P. Moore· 2 shared T. Rossouw· 2 shared V. Ueckermann· 2 shared

Activity by Year

2021-2022 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 35 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersImmunology

L. Morris

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Fc effector activity and neutralization against SARS-CoV-2 BA.4 is compromised in convalescent sera, regardless of the infecting variant

S. Richardson, P. Kgagudi, N. P. Manamela, H. Kaldine, E. Venter, T. Pillay, B. E. Lambson, M. van der Mescht, T. Hermanus, Z. de Beer, T. de Villier, A. Bodenstein, G. van den Berg, M. du Pisanie, W. Burgers, , P. Moore

This study shows that convalescent sera and post-vaccination breakthrough infections have reduced neutralization and ADCC activity against SARS-CoV-2 BA.4, despite prior infection with different variants.

bioRxiv · Jul 14, 2022 · PreprintImmunology

Neutralizing antibodies elicited by the Ad26.COV2.S COVID-19 vaccine show reduced activity against 501Y.V2 (B.1.351), despite protection against severe disease by this variant.

P. Moore, T. Moyo, T. Hermanus, P. Kgagudi, F. Ayres, Z. Makhado, J. Sadoff, M. Le Gars, G. van Roey, C. Crowther, N. Garrett, L.-G. Bekker, L. Morris, H. Schuitemaker, G. Gray

The study assesses neutralizing antibody activity against 501Y.V2 variant post-Ad26.COV2.S vaccination, finding reduced neutralization but potential protection via other immune mechanisms.

bioRxiv · Jun 9, 2021 · PreprintImmunology

Elicitation of neutralizing antibody responses to HIV-1 immunization with nanoparticle vaccine platforms

A. A. Murji, J. S. Qin, T. Hermanus, L. Morris, I. Georgiev

This study evaluates two nanoparticle vaccine strategies to elicit broadly neutralizing antibodies against HIV-1 by incorporating Env diversity from clade A and C strains, showing neutralization in mice and guinea pigs.

bioRxiv · Jun 3, 2021Immunology

SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma

C. K. Wibmer, F. Ayres, T. Hermanus, M. Madzivhandila, P. Kgagudi, B. Oosthuysen, B. E. Lambson, T. de Oliveira, M. Vermeulen, K. van den Berg, T. Rossouw, M. Boswell, V. Ueckermann, S. Meiring, A. von Gottberg, , P. L. Moore

This study shows that SARS-CoV-2 501Y.V2 pseudovirus escapes neutralization by South African convalescent plasma but not binding, suggesting potential for reinfection and reduced vaccine efficacy.

bioRxiv · Jan 18, 2021Immunology